The latest data shows that breast cancer has become the largest cancer in the world, and its incidence rate ranks first among malignant tumors. Its 5-year survival rate of breast cancer is nearly 90%, essentially similar to the management of chronic diseases. Recently, in order to improve the public's awareness of the era of chronic disease management of breast cancer, our reporters have conducted in-depth online and offline exchanges and discussions with clinical experts on hot topics of breast cancer prevention and treatment. Medical experts from Guangzhou, Foshan, Zhongshan, Dongguan, Yangjiang, Heyuan, Shantou, Chaozhou, Jieyang and other places participated in this science popularization activity. Interview experts: Zhao Xiangwen and Chen Jian'an. Zhao Xiangwen, Vice President and Director of Weight Loss Center of Xiaolan People's Hospital in Zhongshan City, Chen Jian'an, Chief Physician of General Surgery, Director of Breast Surgery Department of Xiaolan People's Hospital in Zhongshan City, Master of Surgery, Chief Physician of Surgery (I), has entered the new medical insurance catalog - "Subcutaneous Preparation of Trastuzumab" Helps High Quality Development of Public Hospitals. On December 13, 2023, the National Medical Insurance Administration announced the adjustment results of the national medical insurance catalog in 2023, with a total of 126 drugs newly added to the national medical insurance drug catalog, including 21 types of cancer drugs. The "subcutaneous preparation" of trastuzumab for breast cancer treatment was included in the list of new medical insurance, and was officially implemented on January 1, 2024. Professor Chen Jian'an stated that Zhongshan Xiaolan People's Hospital has made tremendous progress in the field of breast cancer after several generations of specialized doctors. This is not only due to the efforts of several generations of doctors and the trust of patients, but also thanks to the support of various policies. In 2023, the outpatient volume exceeded 15000, with nearly 2000 discharges and an annual surgical volume of over 1000. All indicators have steadily increased, and the specialized department is in a stable and healthy development state. Professor Chen Jian'an introduced that the Breast Department of Xiaolan People's Hospital has GE's LOGIQ E8 high-end color ultrasound diagnostic instrument and Anke minimally invasive breast rotary cutting machine. The doctors in the department have independent diagnostic and biopsy capabilities, and can quickly complete the preliminary diagnosis and live examination of breast tumors using various devices within the department; The hospital has high-end professional breast X-ray imaging equipment and 3T magnetic resonance scanners, which can provide more accurate localization and qualitative diagnosis of suspicious breast lesions; Our pathology laboratory can perform routine HE staining on breast biopsy specimens to quickly and accurately determine the nature, classification, and grading of tumors. Accurate molecular typing can also be performed through immunohistochemistry. In addition, for breast cancer patients in need, BRCA gene testing, targeted therapy related FISH gene testing, chemotherapy related 21 gene testing, and immunotherapy related PD1 testing can also be performed, providing more detailed information for clinical diagnosis, prognosis, and treatment of patients. The biggest feature of this specialty is to follow the latest guidelines and expert consensus at home and abroad for rapid diagnosis and comprehensive treatment of breast cancer patients. The treatment mode of breast cancer has undergone revolutionary changes in recent decades. Firstly, surgery has shifted from maximum tolerable treatment to minimum effective treatment. Surgery is no longer as simple and crude as before, but rather uses surgery combined with other methods to help patients preserve their breasts and ensure their appearance as much as possible; Some parts